Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

NCT00986284 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

102

Enrollment

OTHER

Sponsor class

Stopped Lack of patients and some progressed disease soon after surgery

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: gefitinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital